Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists. Export

@article{citeulike:3771947, abstract = {Evidence suggests that activation of 5-HT1A receptors leads to inhibition of 5-HT2-mediated behavior. The purpose of this study was to investigate the interaction between 5-HT1A and 5-HT2 receptor-mediated hormone secretion. Rats were pretreated with the 5-HT1A agonists buspirone (0, 0.5, 2.0 mg/kg, i.p.), 8-OH-DPAT (0, 0.05, 0.2 mg/kg, s.c.) or ipsapirone (0, 1.0, 2.5 mg/kg, i.p.), 45 min before decapitation. The 5-HT2 agonist DOI was administered (0-10 mg/kg, i.p.) 15 min after injection of the 5-HT1A agonists. The three 5-HT1A agonists differentially altered the DOI-induced increase of concentrations of hormone in plasma. None of the three 5-HT1A agonists influenced the basal levels of renin, ACTH and prolactin but 8-OH-DPAT and buspirone increased the basal level of corticosterone in plasma. Also, 8-OH-DPAT increased the effects of DOI on the concentration of ACTH in plasma but ipsapirone and buspirone did not. None of the 5-HT1A agonists significantly affected DOI-induced increase of concentration of corticosterone in plasma. Buspirone and 8-OH-DPAT potentiated the effect of DOI on prolactin in plasma, but ipsapirone did not. Ipsapirone potentiated the effect of DOI on the concentration of renin in plasma but this effect was not observed in 8-OH-DPAT- and buspirone-pretreated rats. The results do not support the hypothesis for a functional interaction between 5-HT1A and 5-HT2 receptors, since the three 5-HT1A agonists did not have the same influence on the hormonal effects of DOI.}, author = {Li, Q. and Rittenhouse, P. A. and Levy, A. D. and Alvarez Sanz, M. C. and Van de Kar, L. D.}, citeulike-article-id = {3771947}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/1359439}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=1359439}, issn = {0028-3908}, journal = {Neuropharmacology}, keywords = {5ht, 5ht-1a, 5ht-2a, 5ht-2c, doi}, month = {October}, number = {10}, pages = {983--989}, posted-at = {2008-12-11 00:32:05}, priority = {2}, title = {Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/1359439}, volume = {31}, year = {1992} }

TY - JOUR ID - citeulike:3771947 L3 - citeulike-article-id:3771947 N2 - Evidence suggests that activation of 5-HT1A receptors leads to inhibition of 5-HT2-mediated behavior. The purpose of this study was to investigate the interaction between 5-HT1A and 5-HT2 receptor-mediated hormone secretion. Rats were pretreated with the 5-HT1A agonists buspirone (0, 0.5, 2.0 mg/kg, i.p.), 8-OH-DPAT (0, 0.05, 0.2 mg/kg, s.c.) or ipsapirone (0, 1.0, 2.5 mg/kg, i.p.), 45 min before decapitation. The 5-HT2 agonist DOI was administered (0-10 mg/kg, i.p.) 15 min after injection of the 5-HT1A agonists. The three 5-HT1A agonists differentially altered the DOI-induced increase of concentrations of hormone in plasma. None of the three 5-HT1A agonists influenced the basal levels of renin, ACTH and prolactin but 8-OH-DPAT and buspirone increased the basal level of corticosterone in plasma. Also, 8-OH-DPAT increased the effects of DOI on the concentration of ACTH in plasma but ipsapirone and buspirone did not. None of the 5-HT1A agonists significantly affected DOI-induced increase of concentration of corticosterone in plasma. Buspirone and 8-OH-DPAT potentiated the effect of DOI on prolactin in plasma, but ipsapirone did not. Ipsapirone potentiated the effect of DOI on the concentration of renin in plasma but this effect was not observed in 8-OH-DPAT- and buspirone-pretreated rats. The results do not support the hypothesis for a functional interaction between 5-HT1A and 5-HT2 receptors, since the three 5-HT1A agonists did not have the same influence on the hormonal effects of DOI. IS - 10 JF - Neuropharmacology SN - 0028-3908 EP - 989 TI - Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists. VL - 31 SP - 983 KW - 5ht KW - 5ht-1a KW - 5ht-2a KW - 5ht-2c KW - doi AU - Li, Q AU - Rittenhouse, PA AU - Levy, AD AU - Alvarez Sanz, MC AU - Van de Kar, LD PY - 1992/10// UR - http://view.ncbi.nlm.nih.gov/pubmed/1359439 ER -